NCT02986321View on ClinicalTrials.gov

A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD

PHASE2CompletedINTERVENTIONAL

Enrollment

1,130

Participants

Timeline

Start Date

December 15, 2016

Primary Completion Date

October 4, 2017

Study Completion Date

January 9, 2018

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

CHF6001

Dose response: Test one of 4 different doses of CHF6001

DRUG

Budesonide

active control

DRUG

Placebo

placebo control

All Listed Sponsors

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT02986321 - A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD | Biotech Hunter | Biotech Hunter